NEWTOWN, PA — Helius Medical Technologies, Inc. (Nasdaq: HSDT)this week announced the addition of Neurology Center of New England, P.C. (“NCNE”) to its Therapeutic Experience Program (TEP). NCNE joins four other Centers of Excellence in this company-sponsored open-label observational trial designed to evaluate the impact of subjects’ adherence to Portable Neuromodulation Stimulator (PoNS) therapy in patients with multiple sclerosis (MS). The initiative will be led by Dr. Salvatore Napoli, Medical Director of NCNE.
“Dr. Napoli and his team are important contributors to our PTAP program, and we are elated about their participation in the TEP study. NCNE is a highly reputable medical center known for its high-touch, integrated approach to treating MS and other neurological conditions. The center’s unique approach to patient care will further enhance our understanding of the impact of PoNS therapy, as applied in real-world clinical settings, on therapeutic outcome,” said Antonella Favit-Van Pelt, M.D., Ph.D., Helius’ Chief Medical Officer.
“It’s been well established that many people suffering the physical symptoms of MS are able to manage their disease progression with advanced pharmacological and non-pharmacological therapeutic interventions. PoNS therapy has shown the ability to improve gait and balance in patients with MS, and we are thrilled to include this important treatment in our broad spectrum of high-quality neurological care,” stated Dr. Napoli.
Thanks for visiting! Looking for some Chester County pride? We got you covered! Shop our MyChesCo store and show your love for Chester County, Pennsylvania. We got shirts, hats, and more – all with a unique ChesCo flair. Plus, proceeds from each purchase helps support our mission of bringing reliable information and resources to the people of Chester County.